Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors

被引:432
作者
Zhao, YH
Le, J
Abraham, MH
Hersey, A
Eddershaw, PJ
Luscombe, CN
Boutina, D
Beck, G
Sherborne, B
Cooper, I
Platts, JA
机构
[1] UCL, Dept Chem, London WC1H 0AJ, England
[2] Glaxo Wellcome Res & Dev, BioMet, Technol & Informat Grp, Ware SG12 0DP, Herts, England
[3] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[4] Cardiff Univ, Dept Chem, Cardiff CF10 3TB, S Glam, Wales
关键词
intestinal absorption; QSAR; solvation equation; solubility;
D O I
10.1002/jps.1031
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The human intestinal absorption of 241 drugs was evaluated. Three main methods were used to determine the human intestinal absorption: bioavailability, percentage of urinary excretion of drug-related material following oral administration, and the ratio of cumulative urinary excretion of drug-related material following oral and intravenous administration. The general solvation equation developed by Abraham's group was used to model the human intestinal absorption data of 169 drugs we considered to have reliable data. The model contains five Abraham descriptors calculated by the ABSOLV program. The results show that Abraham descriptors can successfully predict human intestinal absorption if the human absorption data is carefully classified based on solubility and administration dose to humans. (C) 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90:749-784, 2001.
引用
收藏
页码:749 / 784
页数:36
相关论文
共 272 条
[71]   CYCLOSPORINE CLINICAL PHARMACOKINETICS [J].
FAHR, A .
CLINICAL PHARMACOKINETICS, 1993, 24 (06) :472-495
[72]   THE METABOLISM OF CARFECILLIN IN RAT, DOG AND MAN [J].
FILER, CW ;
HUMPHREY, MJ ;
JEFFERY, DJ ;
JONES, KH ;
LANGLEY, PF .
XENOBIOTICA, 1980, 10 (10) :761-769
[73]   PHARMACOKINETICS OF BUPROPION, A NOVEL ANTI-DEPRESSANT AGENT, FOLLOWING ORAL-ADMINISTRATION TO HEALTHY-SUBJECTS [J].
FINDLAY, JWA ;
FLEET, JV ;
SMITH, PG ;
BUTZ, RF ;
HINTON, ML ;
BLUM, MR ;
SCHROEDER, DH .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (02) :127-135
[74]   EFFECT OF DOSE AND FOOD ON THE BIOAVAILABILITY OF CEFUROXIME AXETIL [J].
FINN, A ;
STRAUGHN, A ;
MEYER, M ;
CHUBB, J .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1987, 8 (06) :519-526
[75]  
FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575
[76]   CLINICAL PHARMACOKINETICS OF PARACETAMOL [J].
FORREST, JAH ;
CLEMENTS, JA ;
PRESCOTT, LF .
CLINICAL PHARMACOKINETICS, 1982, 7 (02) :93-107
[77]  
Foster RJ., 1990, ANAL PROFILES DRUG S, V19, P1, DOI 10.1016/S0099-5428(08)60362-7
[78]   THE CLINICAL-PHARMACOLOGY, PHARMACOKINETICS AND METABOLISM OF SUMATRIPTAN [J].
FOWLER, PA ;
LACEY, LF ;
THOMAS, M ;
KEENE, ON ;
TANNER, RJN ;
BABER, NS .
EUROPEAN NEUROLOGY, 1991, 31 (05) :291-294
[79]  
FREY BM, 1984, PHARM ACTA HELV, V59, P301
[80]   BETAXOLOL - A NEW LONG-ACTING BETA-1-SELECTIVE ADRENERGIC BLOCKER [J].
FRISHMAN, WH ;
TEPPER, D ;
LAZAR, EJ ;
BEHRMAN, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (08) :686-692